Thomas Story & Son LLC Acquires 944 Shares of Johnson & Johnson $JNJ

Thomas Story & Son LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,855 shares of the company’s stock after purchasing an additional 944 shares during the quarter. Johnson & Johnson accounts for 3.7% of Thomas Story & Son LLC’s holdings, making the stock its 11th largest position. Thomas Story & Son LLC’s holdings in Johnson & Johnson were worth $9,754,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Mar Vista Investment Partners LLC raised its holdings in Johnson & Johnson by 2.5% in the 2nd quarter. Mar Vista Investment Partners LLC now owns 189,441 shares of the company’s stock valued at $28,937,000 after acquiring an additional 4,655 shares in the last quarter. Western Wealth Management LLC increased its position in shares of Johnson & Johnson by 3.7% in the second quarter. Western Wealth Management LLC now owns 15,282 shares of the company’s stock worth $2,334,000 after purchasing an additional 550 shares during the period. Bell Investment Advisors Inc raised its stake in Johnson & Johnson by 49.7% in the second quarter. Bell Investment Advisors Inc now owns 1,671 shares of the company’s stock valued at $255,000 after purchasing an additional 555 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in Johnson & Johnson during the second quarter worth about $2,191,000. Finally, Summitry LLC grew its stake in Johnson & Johnson by 11.8% during the second quarter. Summitry LLC now owns 47,150 shares of the company’s stock worth $7,202,000 after buying an additional 4,960 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. Bank of America boosted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research note on Monday, October 20th. HSBC raised their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ opened at $196.00 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $197.18. The stock has a market capitalization of $472.22 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38. The stock has a fifty day moving average of $185.81 and a 200-day moving average of $170.04.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.